Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals Inc (NQ: APLS )

47.52 +0.64 (+1.37%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 7, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 663,298
Open 46.58
Bid (Size) 46.09 (50)
Ask (Size) 68.00 (5)
Prev. Close 46.88
Today's Range 46.57 - 48.12
52wk Range 33.32 - 70.00
Shares Outstanding 110,575,547
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market
Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years. 
Via Benzinga

Performance

YTD
-2.56%
-2.56%
1 Month
-0.21%
-0.21%
3 Month
-26.04%
-26.04%
6 Month
+8.37%
+8.37%
1 Year
+14.70%
+14.70%

More News

Read More
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
Why Are Apellis Pharmaceuticals Shares Falling Today?
Via Benzinga
Why InMed Pharmaceuticals Shares Tumbled 28%; Here Are 67 Biggest Movers From Friday
Via Benzinga
Foot Locker, Ross Stores, Palo Alto Networks, And Other Big Gainers From Friday
Via Benzinga
Why PaxMedica Shares Are Trading Higher By Over 53%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Apellis Pharma Shares Jump As FDA Accepts Its Lead Product Application For Eye Disease
Via Benzinga
Apellis Pharmaceuticals Surges On New Review Date For Eye-Disease Treatment
Via Investor's Business Daily
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 10, 2022
Via Benzinga
5 Analysts Have This to Say About Apellis Pharmaceuticals
Via Benzinga
Apellis Pharmaceuticals Reports Third Quarter 2022 Financial Results
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
Yelp, Twilio, Atlassian, And Other Big Losers From Friday
Via Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
Apellis Pharma Crashes On Unexpected Delay For Eye Drug — A Boon For Iveric Bio
Via Investor's Business Daily
Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday
Via Benzinga
Why Yelp Shares Are Trading Lower By 15%? Here Are 86 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why Starbucks Shares Are Trading Higher; Here Are 43 Stocks Moving Premarket
Via Benzinga
Apellis Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy (GA)
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
Apellis to Present New Long-Term Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) in PNH Patients at 2022 ASH Annual Meeting
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.